CONDENSED INTERIM FINANCIAL STATEMENTS 2022







CONTENTS

- Directors' declaration
- 3 Interim income statement
- 4 Interim statement of comprehensive income
- 5 Interim statement of changes in equity
- 6 Interim statement of financial position
- 7 Interim statement of cash flows
- 8 17 Notes to the condensed interim financial statements
- 18 19 Company Directory

Directors' Declaration

In the opinion of the directors of Comvita Limited, the condensed interim financial statements and the notes, on pages 3 to 17:

- comply with New Zealand generally accepted accounting practice and fairly state the financial
 position of the Group as at 31 December 2021 and the results of their operations and cash flows for
 the period ended on that date
- have been prepared using appropriate accounting policies, which unless otherwise stated have been consistently applied and supported by reasonable judgements and estimates

The Directors believe that proper accounting records have been kept which enable, with reasonable accuracy, the determination of the financial position of the Group and facilitate compliance of the financial statements with the Financial Reporting Act 2013 and the Financial Markets Conduct Act 2013.

The Directors consider that they have taken adequate steps to safeguard the assets of the Group, and to prevent and detect fraud and other irregularities. Internal control procedures are also considered to be sufficient to provide reasonable assurance as to the integrity and reliability of the financial statements.

The Directors are pleased to present the financial statements of Comvita Limited for the period ended 31 December 2021.

For and on behalf of the Board of Directors:

Brett Hewlett 23 February 2022

Luke Bunt 23 February 2022

Interim Income Statement

| For the six months ended | | 31 December 2021 | 31 December 2020 |
|---|------|------------------|------------------|
| In thousands of New Zealand dollars | Note | Unaudited | Unaudited |
| | | | |
| Revenue | | 104,942 | 98,885 |
| Cost of sales | | (45,542) | (50,385) |
| Gross profit | | 59,400 | 48,500 |
| Other income | | 801 | 2,001 |
| Marketing expenses | | (13,277) | (10,979) |
| Selling and distribution expenses | | (23,259) | (22,252) |
| Administrative and other operating expenses | | (16,476) | (12,113) |
| Operating profit before financing costs | | 7,189 | 5,157 |
| Finance income | 5 | 140 | 516 |
| Finance expenses | 5 | (1,269) | (1,250) |
| Net finance costs | | (1,129) | (734) |
| Share of loss of equity accounted investees | 8 | (196) | (8) |
| Profit before income tax | | 5,864 | 4,415 |
| Income tax | | (2,375) | (960) |
| Profit for the period | | 3,489 | 3,455 |
| Earnings per share: | | | |
| Basic earnings per share (NZ cents) | 6 | 4.97 | 4.95 |
| Diluted earnings per share (NZ cents) | 6 | 4.95 | 4.95 |
| Diluted earnings per stidle (NZ terits) | 0 | 4.75 | 4.73 |

| Supplementary non-GAAP information – EBITDA* | 18 | 12,084 | 10,595 |
|--|----|--------|--------|
|--|----|--------|--------|

^{*}EBITDA is a non-GAAP measure. We monitor this as a key performance indicator and believe it assists investors in assessing the performance of the core operations of our business. A reconciliation of EBITDA to profit before tax is provided in note 18.

 $The \ notes \ on \ pages \ 8 \ to \ 17 \ are \ an \ integral \ part \ of \ these \ condensed \ interim \ financial \ statements.$

Interim Statement of COMPREHENSIVE INCOME

| For the six months ended | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| In thousands of New Zealand dollars | Unaudited | Unaudited |
| Profit for the period | 3,489 | 3,455 |
| Items that are or may be reclassified subsequently to the income statement | | |
| Foreign currency translation differences for foreign operations | 471 | (2,058) |
| Fair value movement – available for sale reserve | - | 396 |
| Effective portion of changes in fair value of cash flow hedges | (884) | 1,208 |
| Foreign investor tax credits received | 68 | - |
| Income tax on these items | 413 | (262) |
| Income and expense recognised directly in other comprehensive income | 68 | (716) |
| Total comprehensive income for the period | 3,557 | 2,739 |

Interim Statement of CHANGES IN EQUITY

| For the six months ended 31 December 2021 In thousands of New Zealand dollars | Share capital | Foreign currency translation reserve | Hedging reserve | Fair value reserve | Retained earnings | Total |
|--|------------------|---|--------------------|-----------------------|----------------------|---------|
| Balance at 1 July 2020 | 200,104 | (3,809) | (527) | (2,640) | 18,620 | 211,748 |
| Total comprehensive income for the period | | | | | | |
| Profit after tax for the period | - | - | - | - | 3,455 | 3,455 |
| Other comprehensive income (net of tax): | | | | | | |
| Fair value movement in equity instruments | - | - | - | 396 | - | 396 |
| Disposal of equity instruments | - | - | - | 2,244 | (2,244) | - |
| Foreign currency translation differences for foreign operations | - | (1,982) | - | - | - | (1,982) |
| Effective portion of changes in fair value of cash flow hedges | - | - | 870 | - | - | 870 |
| Total other comprehensive income for the period | - | (1,982) | 870 | 2,640 | (2,244) | (716) |
| Total comprehensive income for the period | _ | (1,982) | 870 | 2,640 | 1,211 | 2,739 |
| Transactions with owners, recorded directly in equity | | | | | | |
| Share based payment | _ | _ | _ | _ | 117 | 117 |
| Redemption of ordinary shares - executive share scheme | (6) | - | - | - | - | (6) |
| Redemption of ordinary shares - staff share scheme | (14) | _ | _ | _ | _ | (14) |
| Supplier share scheme | 407 | _ | _ | _ | _ | 407 |
| Total transactions with owners | 387 | | | | 117 | 504 |
| Balance at 31 December 2020 | 200,491 | (5,791) | 343 | | 19,948 | 214,991 |
| | | (-), | | | | |
| Balance at 1 July 2021 | 201,839 | (4,862) | (1,211) | - | 26,114 | 221,880 |
| Total comprehensive income for the period | | | | | | |
| Profit after tax for the period | - | - | - | - | 3,489 | 3,489 |
| Other comprehensive income (net of tax) | | | | | | |
| Foreign investor tax credits received | - | - | - | - | 68 | 68 |
| Foreign currency translation differences for foreign operations | - | 636 | - | - | - | 636 |
| Effective portion of changes in fair value of cash flow hedges | - | - | (636) | - | - | (636) |
| Total other comprehensive income for the period | - | 636 | (636) | - | 68 | 68 |
| Total comprehensive income for the period | - | 636 | (636) | - | 3,557 | 3,557 |
| Transactions with owners, recorded directly in equity | | | | | | |
| Share based payments | - | - | - | - | 264 | 264 |
| Purchase of treasury stock | (1,549) | - | - | - | - | (1,549) |
| Issue of ordinary schemes - PSR scheme | 299 | - | - | - | - | 299 |
| Redemption of ordinary shares - staff share scheme | (10) | - | - | - | - | (10) |
| Issue of treasury stock - Supplier share scheme | 541 | - | - | - | (37) | 504 |
| Dividend paid (note 15) | - | | - | - | (2,893) | (2,893) |
| Total transactions with owners | (719) | - | - | - | (2,666) | (3,385) |
| Balance at 31 December 2021 | 201,120 | (4,226) | (1,847) | - | 27,005 | 222,052 |

Interim Statement of FINANCIAL POSITION

| Note | |
|--|----------------------|
| Property, plant and equipment 64,462 60,262 Intangible assets and goodwill 39,646 38,791 Right of use assets 12,451 12,992 Biological assets 3,808 3,794 Investments 8 11,745 6,261 Deferred tax asset 6,200 8,440 Total non-current assets 138,312 130,540 Inventory 10 111,776 98,549 Trade receivables 32,308 26,223 Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 38,9 Tox receivable 467 528 Total assets 317,608 282,748 Equity Sundry receivable 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 9,687 9,989 Deferred tax liabilities 533 329 Total non-current liabilities 533 329 Total non-current liabilities 12,128 40,621 Total non-current liabilities 12,128 Total non-current liabilities 12,128 Total non-current liabilities 12,128 Total non-current liabilities 12,128 Total non | June 2021 Audited |
| Property, plant and equipment 64,462 60,262 Intangible assets and goodwill 39,646 38,791 Right of use assets 12,451 12,992 Biological assets 3,808 3,794 Investments 8 11,745 6,261 Deferred tax asset 6,200 8,440 Total non-current assets 138,312 130,540 Inventory 10 111,776 98,549 Trade receivables 32,308 26,223 Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Total current assets 179,296 152,208 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity 15,448 200,491 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 9,687 9,989 | Audited |
| Intongible assets and goodwill 39,646 38,791 Right of use assets 12,451 12,992 | 42.24E |
| Right of use assets 12,451 12,992 Biological assets 3,808 3,794 Investments 8 11,745 6,261 Deferred tax asset 6,200 8,440 Total non-current assets 138,312 130,540 Inventory 10 111,776 98,549 Trade receivables 32,308 26,223 Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Tax receivable 467 528 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity 18sued capital 201,120 200,491 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 63,345 |
| Biological assets 3,808 3,794 Investments 8 11,745 6,261 Deferred tax asset 6,200 8,440 Total non-current assets 138,312 130,540 Inventory 10 111,776 98,549 Trade receivables 32,308 26,223 Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Total current assets 179,296 152,208 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities Loans and borrowings 11 - 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 38,046 |
| Investments | 13,035 |
| Deferred tax asset | 3,814 |
| Total non-current assets 138,312 130,540 | 6,849 |
| Inventory | 7,209 |
| Trade receivables 32,308 26,223 Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Tax receivable 467 528 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 20,03 20,03 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 132,298 |
| Trade receivables 32,308 26,223 Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Tax receivable 467 528 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity 18sued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 20,0491 20,0491 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 101 000 |
| Sundry receivables 7 15,392 12,122 Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Tax receivable 467 528 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 200,491 200,491 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 101,008 |
| Cash and cash equivalents 11 19,353 14,397 Derivatives 9 - 389 Tax receivable 467 528 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 200,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 23,523 |
| Derivatives 9 | 13,463 |
| Tax receivable 467 528 Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 9,687 9,989 Deferred tax liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 16,267 |
| Total current assets 179,296 152,208 Total assets 317,608 282,748 Equity Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | - |
| Total assets 317,608 282,748 Equity 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 50 |
| Equity Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 154,311 |
| Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity Liabilities Loans and borrowings 11 - 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 286,609 |
| Issued capital 201,120 200,491 Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity Liabilities Loans and borrowings 11 - 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | |
| Retained earnings 27,005 19,948 Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 201,839 |
| Reserves (6,073) (5,448) Total equity 222,052 214,991 Liabilities 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 26,114 |
| Total equity 222,052 214,991 Liabilities 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | (6,073) |
| Liabilities 11 - 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 221,880 |
| Loans and borrowings 11 - 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 221,000 |
| Loans and borrowings 11 - 28,300 Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | |
| Lease liabilities 9,687 9,989 Deferred tax liability 1,908 2,003 Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 20,850 |
| Deferred tax liability Employee benefits 533 Total non-current liabilities 1,908 2,003 329 40,621 | 9,950 |
| Employee benefits 533 329 Total non-current liabilities 12,128 40,621 | 1,962 |
| Total non-current liabilities 12,128 40,621 | 539 |
| | 33,301 |
| Trade and other payables 25.371 17.510 | - |
| | 18,869 |
| Lease liability 3,388 3,451 | 3,631 |
| Employee benefits 4,015 3,574 | 5,514 |
| Tax payable 2,464 2,601 | 1,766 |
| Derivatives 9 2,541 - | 1,648 |
| Loans and borrowings 11 45,649 - | - |
| Total current liabilities 83,428 27,136 | 31,428 |
| Total liabilities 95,556 67,757 | 64,729 |
| Total equity and liabilities 317,608 282,748 | 286,609 |

Interim Statement of CASH FLOWS

| For the six months ended | | | |
|--|-------|----------------------------|----------------------------|
| In thousands of New Zealand dollars | NI-+- | 31 December 2021 Unaudited | 31 December 2020 Unaudited |
| | Note | Unavaited | Undudited |
| Receipts from customers | | 97,616 | 89,910 |
| Payments to suppliers and employees | | (100,566) | (78,707) |
| Interest received | | 2 | 11 |
| Interest paid | | (1,144) | (1,250) |
| Taxation paid | | (764) | (535) |
| Net cash flows from operating activities | 12 | (4,856) | 9,429 |
| | | | |
| Investment in equity accounted investees | | (5,092) | - |
| Interest from related parties | | 28 | 18 |
| Proceeds from disposal of investment | | - | 396 |
| Loans to equity accounted investees | | 250 | (1,493) |
| Payment for the acquisition of property, plant and equipment | | (3,463) | (5,394) |
| Receipt from disposal of property, plant and equipment | | 75 | 997 |
| Payment for the acquisition of intangibles | | (2,450) | (184) |
| Net cash flows from investing activities | | (10,652) | (5,660) |
| Purchase of treasury stock | | (1,549) | |
| • | | | (20) |
| Payment for redemption of employee shares | | (10) | , , |
| Repayment of lease liabilities | | (1,934) | (1,623) |
| Drawdown/(repayment) of loans and borrowings | | 24,799 | (3,900) |
| Payment of dividends | | (2,893) | - |
| Net cash flows from financing activities | | 18,413 | (5,543) |
| Net increase in cash and cash equivalents | | 2,905 | (1,774) |
| Cash and cash equivalents at the beginning of the period | | 16,267 | 16,680 |
| Effect of exchange rate fluctuations on cash held | | 181 | (509) |
| Cash and cash equivalents at the end of the period | | 19,353 | 14,397 |
| | | | |
| Represented as: | | | |
| Cash and cash equivalents | 11 | 19,353 | 14,397 |
| Total | | 19,353 | 14,397 |

Comvita Condensed Interim Financial Statements 2022 - P9

Notes to the Condensed Interim Financial Statements

1. REPORTING ENTITY

Comvita Limited (the "Company") is a company domiciled in New Zealand and registered under the Companies Act 1993 and listed on the New Zealand Stock Exchange ("NZX"). The Company is an issuer in terms of the Financial Reporting Act 2013 and Financial Markets Conduct Act 2013.

The condensed interim financial statements of the Group for the six months ended 31 December 2021 comprise the Company and its subsidiaries (together referred to as the "Group") and the Group's interest in equity accounted investees.

The principal activity of the Group is that of manufacturing and marketing quality natural health products, apiary ownership and management.

2. BASIS OF PREPARATION

(a) Statement of compliance

The Company is a FMC reporting entity for the purposes of the Financial Reporting Act 2013 and under Part 7 of the Financial Markets Conduct Act 2013. These Financial Statements comply with these Acts and have been prepared in accordance with the New Zealand Equivalents to International Financial Reporting Standards as appropriate for profit-oriented entities.

The condensed interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the group financial statements as at and for the year ended 30 June 2021.

The condensed interim financial statements were approved by the Board of Directors on 23 February 2022.

(b) Basis of measurement

The financial statements have been prepared on the historical cost basis except for derivative financial instruments, financial instruments designated as fair value through other comprehensive income, biological assets and leases which are measured at fair value. Fair values have been determined for measurement and/or disclosure purposes on the same basis as those applied by the Group in the financial statements as at and for the year ended 30 June 2021.

(c) Functional and presentation currency

These financial statements are presented in New Zealand dollars (\$), which is the Company's functional currency. Amounts have been rounded to the nearest thousand.

(d) Use of estimates and judgements

The preparation of condensed interim financial statements in accordance with NZ IAS 34 Interim Financial Reporting requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

In preparing these condensed interim financial statements, the significant judgements made by management in applying the Groups accounting policies and the key sources of estimation uncertainty were the same as those applied to the financial statements as at and for the year ended 30 June 2021.

(e) Covid-19 considerations

Covid-19 considerations Comvita is classified as an 'Essential' business by the New Zealand Government, therefore having no impact on the manufacturing process of the Group. For the period ended 31 December 2021 the Group has not been significantly impacted by COVID-19. There has been a strong demand in sales, in particular in online channels across all markets. An assessment over the carrying value of assets and liabilities has been performed and the Group has recognised provisions where necessary relating to the impact of COVID-19. The Group continues to operate as a going concern and Senior Management continue to closely monitor the situation.

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied in these condensed interim financial statements are the same as those applied in the Group's financial statements as at and for the year ended 30 June 2021.

4. SEGMENT REPORTING

A review of operating segments has been completed in the current year and this has resulted in a change to reported segments. Previously reported segment information has been restated in line with the operating segments described below.

Segment information is presented in the condensed interim financial statements in respect of the Group's contribution segments which are the primary basis of decision making. The contribution segment reporting format reflects the Group's management and internal reporting structure.

Performance is measured based on contribution which is a measure of profitability that the segment contributes to the Group. Contribution is used to measure performance as management believes that such information is most relevant in evaluating the results of certain segments. Inter-segment pricing is determined on an arms-length basis.

Each segment sells Comvita's range of products. Comvita's range of products primarily include products with apiary and other natural ingredients.

The Company is organised primarily by geographic location of its subsidiaries

The Group has five reportable segments as described below:

Greater China This segment reports both revenue and related costs for the China and Hong Kong

markets.

ANZ Australia and New Zealand (ANZ) segment captures both revenue and related costs for

the ANZ market.

Rest of Asia This segment captures both revenue and related costs of all of our Asian operations

and customers excluding Greater China.

North America This segment reports both revenue and

related costs for sales to customers in North

EMEA The Europe, Middle East and Africa (EMEA) segment captures both revenue and related

costs for the EMEA markets.

Notes to the Condensed Interim Financial Statements

4. SEGMENT REPORTING (CONTINUED)

For the six months to 31 December 2021 and 31 December 2020 unaudited

In thousands of New Zealand dollars

| Contribution segments | Greater China | | ANZ | | Rest o | Rest of Asia N | | merica | | | Otl segm | | То | tal | | |
|--|------------------|-----------|---------|--------|--------|----------------|--------|---------|-------|-------|-------------|--------|-------|-------|----------|----------|
| For the six months to 31 December | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 |
| Contribution Segments | | | | | | | | | | | | | | | | |
| Revenue | 47,740 | 47,615 | 18,061 | 18,092 | 12,698 | 12,572 | 17,178 | 11,617 | 2,900 | 3,394 | 98,577 | 93,290 | 6,365 | 5,595 | 104,942 | 98,885 |
| Contribution | 11,986 | 11,232 | 6,051 | 6,279 | 3,252 | 3,747 | 5,296 | 3,031 | 238 | 139 | 26,823 | 24,428 | 531 | 417 | 27,354 | 24,845 |
| | | | | | | | | | | | | | | | | |
| Non attributable (| other corp | oorate ex | penses) | | | | | | | | | | | | (20,966) | (21,689) |
| Financial income and expenses (note 5) | | | | | | | | (1,129) | (734) | | | | | | | |
| Other income | | | | | | | | 801 | 2,001 | | | | | | | |
| Share of profit of equity accounted investees (note 8) | | | | | | | | (196) | (8) | | | | | | | |
| Net profit befor | e tax | | | | | | | | | | | | | | 5,864 | 4,415 |

Total assets

| | December 2021 | December 2020 | June 2021 |
|--|---------------|---------------|-----------|
| In thousands of New Zealand dollars | Unaudited | Unaudited | Audited |
| Total assets for reportable segments | 173,692 | 143,054 | 150,970 |
| Other investments | 8 | 8 | 8 |
| Investment in equity accounted investees | 11,737 | 6,253 | 6,841 |
| Other unallocated assets | 132,171 | 133,433 | 128,790 |
| Consolidated total assets | 317,608 | 282,748 | 286,609 |

5. FINANCIAL INCOME AND EXPENSES

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| | Unaudited | Unaudited |
| Interest income | 134 | 110 |
| Dividend income | 6 | 9 |
| Net foreign exchange gain | - | 397 |
| Finance income | 140 | 516 |
| | | |
| Interest expense on financial liabilities measured at amortised cost | (1,144) | (1,250) |
| Net foreign exchange loss | (125) | - |
| Finance expense | (1,269) | (1,250) |

Notes to the Condensed Interim Financial Statements

6. EARNINGS PER SHARE

| Basic earnings per share - weighted average number of ordinary shares | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| In thousands of shares | Unaudited | Unaudited |
| Issued ordinary shares at beginning of period | 70,300 | 69,780 |
| Effect of shares issued during the period | (151) | 11 |
| Weighted average number of ordinary shares at the end of the period | 70,149 | 69,791 |
| | | |
| Earnings | 3,489 | 3,455 |
| Basic earnings per share (NZ cents) | 4.97 | 4.95 |
| | | |
| Diluted earnings per share – weighted average number of ordinary shares In thousands of shares | 31 December 2021 | 31 December 2020 |
| Weighted average number of ordinary shares (basic) | 70,149 | 69,791 |
| Effect of stock entitlements issued | 351 | - |
| Weighted average number of diluted shares at the end of the period | 70,500 | 69,791 |
| Diluted earnings per share (NZ cents) | 4.95 | 4.95 |

The effect of stock entitlements is Nil where the exercise price is higher than the average share price for the period, in accordance with NZ IAS 33 *Earnings per share*.

7. SUNDRY RECEIVABLES

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2021 |
|--|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Prepayments | 6,874 | 5,946 | 4,360 |
| Loans to equity accounted investees (note 8c) | 4,883 | 4,835 | 5,031 |
| Loan receivable – related parties | - | 567 | - |
| Loan receivable - management personnel (note 13) | 2,757 | 450 | 2,746 |
| Other receivables | 878 | 324 | 1,326 |
| Total sundry receivables | 15,392 | 12,122 | 13,463 |

8. INVESTMENTS

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2021 |
|--|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Investment in equity accounted investees | 11,737 | 6,253 | 6,841 |
| Other investments | 8 | 8 | 8 |
| Total investments | 11,745 | 6,261 | 6,849 |

Notes to the Condensed Interim Financial Statements

8. INVESTMENTS (CONTINUED)

(a) Investments in equity accounted investees comprises:

| | Country of Incorporation | Ownership Interest Held | Balance Date | Principal Activity |
|-------------------------------|-----------------------------|----------------------------|-----------------|--|
| Makino Station Limited | New Zealand | 50% | 30 June | Apiary and land ownership |
| Gan Supply JV Limited | New Zealand | 33% | 30 June | Restructure and Winding up Agreement signed 4 June 2021 |
| Medibee Pty Limited "Medibee" | Australia | 50% | 30 June | Apiary |
| Apiter S.A. "Apiter" | Uruguay | 20% | 31 July | Manufacturing, selling and distribution |
| Caravan Honey Company | USA | 50% | 31 Dec | Development and commercialisation of products made with Comvita Mānuka honey and propolis for topical use |

Medibe

Medibee Apiaries has a funding arrangement with HSBC and Comvita has signed a several guarantee for its share of the loan facility, which is AUD \$4,500,000 at balance date.

Caravan Honey Company

On 22 December 2021 Comvita Limited entered a stock purchase agreement to purchase 4,500,000 shares for USD\$3,379,500 in a newly established US domiciled entity, Caravan Honey Company. Comvita currently has 50% ownership and joint control of this entity.

(b) Carrying value of equity accounted investees

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2021 |
|---|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Opening balance – 1 July | 6,841 | 6,261 | 6,261 |
| Acquisition | 5,092 | - | - |
| Dividends received | - | - | (363) |
| Share of (loss)/profit | (196) | (8) | 992 |
| Foreign exchange movements recognised in other comprehensive income | - | - | (49) |
| Closing balance | 11,737 | 6,253 | 6,841 |

(c) Loans to equity accounted investees

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2021 |
|-------------------------------------|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Loan and interest receivable | | | |
| Makino | 3,999 | 4,089 | 4,168 |
| Apiter | 884 | 534 | 863 |
| Gan Supply JV | - | 212 | - |
| Total | 4,883 | 4,835 | 5,031 |

Makino

Interest is accrued on the balance of loan at a rate of 5.34% p.a. (2020: 5.34%). Interest income for the six months ended 31 December 2021 was \$81,000 (2020: \$81,000).

Apiter:

The loan is denominated in USD. Interest is accrued on the balance of the loan at a rate of 3.5% p.a. (2020: 3.5%). Interest income for the six month ended 31 December 2021 was \$9,000 (2020: \$8,000).

All loans to equity accounted investees are repayable on demand.

Notes to the Condensed Interim Financial Statements

8. INVESTMENTS IN EQUITY ACCOUNTED INVESTEES (CONTINUED)

(d) Transactions with equity accounted investees

| In thousands of New Zealand dollars | Sale of goods | and services | Purchases of goo | ods and services |
|-------------------------------------|-------------------|------------------|-------------------|------------------|
| | Transaction value | Balance due from | Transaction value | Balance owing to |
| 31 December 2021 | | | | |
| Makino | 80 | - | 1,021 | 113 |
| Gan Supply JV | 1 | - | 40 | - |
| Apiter | - | - | 323 | - |
| | | | | |
| 31 December 2020 | | | | |
| Makino | 58 | - | 402 | - |
| Gan Supply JV | 8 | - | 478 | - |
| Apiter | - | - | 1,509 | - |

9. DERIVATIVES

The table below analyses financial instruments carried at fair value, by valuation method. These are all level 2 on the fair value hierarchy, as they include inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices). There have been no transfers between levels in either direction during the period.

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2020 |
|--|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Derivatives – assets (hedging instrument) | - | 389 | - |
| Total assets | - | 389 | - |
| | | | |
| Derivatives - liabilities (hedging instrument) | (2,541) | - | (1,648) |
| Total liabilities | (2,541) | - | (1,648) |

 $Derivative-assets\ and\ liabilities\ (hedged)\ and\ designated\ at\ fair\ value\ through\ the\ income\ statement.$

The Group's Level 2 fair values for simple over-the-counter derivative financial instruments are based on broker quotes. Those quotes are tested for reasonableness by discounting expected future cash flows using market interest rate for a similar instrument at the measurement date. Fair values reflect the credit risk of the instrument and include adjustments to take account of the credit risk of the Group entity and counterparty when appropriate.

Fair values

The fair value of all financial assets and liabilities is the same as the carrying amount.

Comvita Condensed Interim Financial Statements 2022 - P13

Notes to the Condensed Interim Financial Statements

10. INVENTORY

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2021 |
|-------------------------------------|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Raw materials | 72,062 | 65,733 | 60,762 |
| Work in progress | 1,617 | 314 | 1,049 |
| Finished goods | 38,097 | 32,502 | 39,197 |
| Total inventory | 111,776 | 98,549 | 101,008 |

Inventory disposed of during the period ended 31 December 2021 has been recognised within cost of goods sold - \$324,000 (2020: \$288,000).

11. LOANS AND BORROWINGS

This note provides information about the contractual terms of the Group's interest-bearing loans and borrowings issued and repaid during the periods presented.

Terms and debt repayment schedule

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 | 30 June 2021 |
|--|------------------|------------------|--------------|
| | Unaudited | Unaudited | Audited |
| Balance at beginning of period | 20,850 | 32,200 | 99,250 |
| Drawdown/(repayment) of borrowings - net | 24,799 | (3,900) | (78,400) |
| Balance at end of period | 45,649 | 28,300 | 20,850 |
| Penresented as: | | | |

| Total net debt | 26,296 | 13,903 | 4,583 |
|----------------------------------|----------|----------|----------|
| Less: cash and cash equivalents | (19,353) | (14,397) | (16,267) |
| Total loans and borrowings | 45,649 | 28,300 | 20,850 |
| Non-current loans and borrowings | - | 28,300 | 20,850 |
| Current loans and borrowings | 45,649 | - | - |
| Represented as: | | | |

The Group was in compliance with banking covenants during the period and as at 31 December 2021.

At 31 December 2021, the Group's loans and borrowings had an expiry date of 1st July 2022. An extension letter was executed 14 February 2022 which extended the Group's loans and borrowings expiry date to 1 January 2023.

Notes to the Condensed Interim Financial Statements

12. RECONCILIATION OF THE PROFIT FOR THE PERIOD WITH THE NET CASH FROM OPERATING ACTIVITIES

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 |
|---|------------------|------------------|
| | Unaudited | Unaudited |
| | | |
| Profit for the period | 3,489 | 3,455 |
| Items not involving cash flows: | | |
| Depreciation | 4,338 | 4,045 |
| Amortisation | 873 | 841 |
| Gain on disposal of non-current assets | (51) | (237) |
| Share based payments | 563 | 117 |
| Supplier share scheme – inventory purchase | 504 | 407 |
| Share of profit in equity accounted investees | 196 | 8 |
| Profit adjusted for non-cash items | 9,912 | 8,636 |
| | | |
| Movement in working capital items: | | |
| Change in inventories | (10,768) | 14,130 |
| Change in trade receivables | (8,785) | (8,497) |
| Change in sundry debtors and prepayments | (2,054) | 290 |
| Change in trade and other payables | 4,812 | (5,622) |
| Change in tax payable | 281 | 1,281 |
| Change in deferred tax | 955 | (588) |
| Movement in working capital items from foreign currency translation reserve | 719 | (1,353) |
| Other movements: | | |
| Movement of deferred tax in equity | 418 | (414) |
| Prepayment to equity accounted investee | - | 1,509 |
| Interest income from investing activities | (132) | (99) |
| Foreign investor tax credits | 68 | - |
| Foreign currency reserve | (282) | 156 |
| Net cash from operating activities | (4,856) | 9,429 |

Comvita Condensed Interim Financial Statements 2022 - P15

Notes to the Condensed Interim Financial Statements

13. RELATED PARTIES

(a) Transactions with key management personnel

Key management compensation comprised:

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 |
|-------------------------------------|------------------|------------------|
| | Unaudited | Unaudited |
| Short term employee benefits | 2,195 | 1,910 |
| Share based payments | 349 | 46 |
| Total | 2,544 | 1,956 |

(b) Key management and director loans

Key management compensation comprised:

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| | Unaudited | Unaudited |
| Loan to CEO | 450 | 450 |
| Loan to key management personnel – Leader Share Purchase and Loan Scheme (note 14) | 2,307 | - |
| Total | 2,757 | 450 |

Directors and other key management personnel of the Company control 3.38% (30 June 2021: 2.37%, 31 December 2020: 1.31%) of the voting shares of the Company.

Notes to the Condensed Interim Financial Statements

14. EXECUTIVE EMPLOYEE SHARE SCHEMES

(a) Leader and Share Purchase and Loan Scheme:

On 25 March 2021 Comvita Limited established a Leader Share Purchase & Loan scheme ("LSPLS") to retain key employees and materially align the interests of participants with those of shareholders, by making loans available to eligible employees for the acquisition of fully paid ordinary shares in Comvita.

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 |
|-------------------------------------|------------------|------------------|
| | Unaudited | Unaudited |
| | | |
| Employees in the LSPLS | 8 | - |
| Number of shares held | 738,012 | - |
| % of share capital | 1.05% | - |

(b) Performance Share Rights Scheme:

Comvita Limited has a Performance Share Rights (PSR's) Scheme to incentivise Executives. Upon vesting of the PSR's, shares will be transferred from treasury stock or new shares will be issued in the capital of the Company on the terms and conditions described in the Comvita Limited Performance Share Rights Scheme. Share based payment expenses are recognised over the vesting period of these PSRs.

| In thousands of shares | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| | Unaudited | Unaudited |
| Entitlements outstanding at beginning of period – July | 147 | - |
| Entitlements granted | 387 | 122 |
| Entitlements cancelled | (23) | 25 |
| Shares vested | (44) | - |
| Total | 467 | 147 |

During the period there was 37,516 additional shares issued to employees under the same incentive structure as the PSR scheme. These shares were issued for no consideration from treasury stock.

(c) Executive Share Scheme:

Comvita Limited has an Executive Share Scheme called the Comvita Limited Partly Paid Share Scheme, which is winding down. As at 31 December there is outstanding entitlements of 362,000 shares (2020: 617,000 shares).

15. DIVIDENDS PAID

On 7 October 2021 a final dividend was paid. It was a fully imputed final dividend of \$2,893,000 (4.0 cents per share).

16. CAPITAL COMMITMENTS

At 31 December 2021 the Group has committed to spending \$2,300,000 over the next year. The capital commitment relates to mānuka forest investment and other capital projects.

Comvita Condensed Interim Financial Statements 2022 - P17

Notes to the Condensed Interim Financial Statements

17. SUBSEQUENT EVENTS

Dividends

On 23 February 2022, the Directors approved the payment of a fully imputed final dividend of \$1,760,000 (2.5 cents per share) to be paid on 31 March 2022. As the dividend was declared after balance date it has not been recognised as a liability in these financial statements.

18. SUPPLEMENTARY NON-GAAP INFORMATION - EBITDA

Earnings before interest, tax, depreciation, and amortisation (EBITDA) is a non-GAAP measure. We monitor this as a key performance indicator and believe it assists investors in assessing the performance of the core operations of our business.

| In thousands of New Zealand dollars | 31 December 2021 | 31 December 2020 |
|---|------------------|------------------|
| | Unaudited | Unaudited |
| | | |
| Profit before tax | 5,864 | 4,415 |
| Add back: net finance cost | 1,010 | 1,140 |
| EBIT | 6,874 | 5,555 |
| Add back: depreciation and amortisation | 5,210 | 5,040 |
| EBITDA | 12,084 | 10,595 |

Directory

DIRECTORS

COMVITA Board Of Directors

Brett Donald Hewlett Lucas (Luke) Nicholas Elias Bunt Sarah Jane Kennedy Bridget Coates Robert Malcolm Major Yawen Wu Guangping Zhu David Banfield

BANKERS

Westpac Banking Corporation

Level 8 16 Takutai Square PO Box 934 Auckland, 1142

AUDITORS

KPMG Tauranga

Level 2, 247 Cameron Road Tauranga 3140

REGISTERED OFFICE

Comvita Limited

- 23 Wilson Road South, Paengaroa Private Bag 1, Te Puke 3153 Bay of Plenty, New Zealand
- Phone +64 7 533 1426
- ₱ Fax +64 7 533 1118
- o Freephone 0800 504 959
- Email investor-relations@comvita.com
- www.comvita.co

SOLICITORS

Sharp Tudhope

Level 4 152 Devonport Road Private Bag TG12020 Tauranga 3110

SHARE REGISTRY

Link Market Services Limited

Level 30 PwC Tower 15 Customs Street West Auckland 1010

Directory

NEW ZEALAND

Comvita New Zealand Limited

- 23 Wilson Road South | Paengaroa Private Bag 1 | Te Puke 3153 Bay of Plenty | New Zealand
- ► Phone +64 7 533 1426
- O Freephone 0800 504 959
- ø info@comvita.com

HONG KONG SAR

Comvita HK Limited

- Room 1320 1322 Leighton Centre 77 Leighton Road Causeway Bay | Hong Kong
- ▶ Phone +852 2562 2335
- e cs@comvita.com.hk

KOREA

Comvita Korea Co Limited

- 18F Gwanghwamun Building, 149 Sejong-daero, Jongno-gu, Seoul(03186) | Korea
- ▶ Phone +82 2 2631 0041
- service.korea@comvita.com

UNITED KINGDOM

Comvita UK Limited

- 2nd Floor, 47a High Street Maidenhead, SL61JT United Kingdom
- Phone +44 1628 779 460
- e info@comvita.co.uk

EUROPE

Comvita Europe B.V. Professor J.H.

- Bavincklaan 7 1183 AT Amstelveen | Netherlands
- ▶ Phone +31682065359
- ø info.europe@comvita.com

AUSTRALIA

Comvita Australia Pty Limited

- * 10 Edmondstone Street South Brisbane Queensland 4101 | Australia
- ► Phone +61 7 3845 1400
- 9 Freephone 1800 466 392
 Customer Service 1300 653 436
- ø info@comvita.com.au

JAPAN

Comvita Japan K.K.

- Sangenjaya Horisho Bld 4F
 1-12-39 Taishido, Setagaya-Ku
 Tokyo 154-0004 | Japan
- ▶ Phone +813 6805 4780
- ø info@comvita-jpn.com

CHINA

Comvita Food (China) Limited

- 2501 2502 No. 7018 Sunhope E-Metro, Caitan Road, Futian District
 Shenzhen | China
- ♦ Phone +86 755 8366 1958
- comvita@comvita.com.cn

NORTH AMERICA

Comvita USA Inc.

- 506 Chapala Street Santa Barbara, CA 93101 | USA
- ▶ Phone +1 855 449 2201
- usacustomerservice@comvita.com